Yes, there are several tests that can detect early-onset Alzheimer’s disease, and the options have improved significantly in recent years. Early-onset Alzheimer’s refers to the disease developing before age 65, and it can appear as early as a person’s 30s, though that’s rare. The diagnostic process typically involves a combination of cognitive screening, blood or spinal fluid biomarkers, brain imaging, and in some cases genetic testing.
How the Diagnostic Process Typically Works
Getting tested for early-onset Alzheimer’s usually follows a step-by-step sequence rather than a single definitive test. It often starts with a visit to your primary care doctor, who will run a cognitive screening test in the office, order blood work to rule out other causes of memory problems (like thyroid issues or vitamin B12 deficiency), and request a brain MRI. If those results raise concern, you’ll likely be referred to a neurologist, who can order more specialized biomarker tests to confirm whether Alzheimer’s pathology is present.
This matters because Alzheimer’s has historically been diagnosed late, often years after symptoms first appeared. The brain changes that cause the disease, specifically amyloid plaques, start forming 10 to 20 years before noticeable cognitive symptoms. Another type of brain change, tau tangles, develops 5 to 10 years before symptoms. Modern biomarker tests can now detect these changes much earlier in the process.
Cognitive Screening Tests
The first step is usually a standardized cognitive assessment. The Montreal Cognitive Assessment (MoCA) is one of the most commonly used tools and is better than older screening tests like the Mini-Mental State Examination at catching mild cognitive impairment and early-stage dementia. A MoCA score below 24 is generally considered the threshold for detecting cognitive impairment, and the test picks up mild cognitive impairment with roughly 83% effectiveness.
For younger patients who are still high-functioning, cognitive screening can be tricky. Someone in their 40s or 50s with early-onset Alzheimer’s may still score relatively well on a brief office test despite noticing real changes in their thinking. That’s one reason biomarker testing has become so important: it can confirm or rule out Alzheimer’s biology even when cognitive tests are borderline.
Blood Tests for Alzheimer’s Biomarkers
Blood-based biomarker tests represent the biggest recent advance in Alzheimer’s diagnostics. The most promising measures a protein fragment called p-tau217, which reflects both amyloid and tau buildup in the brain. A meta-analysis of available studies found that a plasma p-tau217 test detects amyloid pathology with 82% sensitivity and 86% specificity, and tau pathology with 83% sensitivity and 83% specificity. In practical terms, that means it correctly identifies most people who have Alzheimer’s biology and correctly clears most people who don’t.
The test performs even better in people who are already showing cognitive symptoms compared to those who are still symptom-free. That makes it particularly useful if you’re experiencing memory or thinking changes and want to know whether Alzheimer’s is the cause. Blood-based biomarker tests are increasingly available through neurologists and some primary care settings, though access varies by location and insurance coverage.
Spinal Fluid Analysis
Cerebrospinal fluid (CSF) testing, done through a lumbar puncture, has been a reliable Alzheimer’s diagnostic tool for longer than blood tests. The key measurement is the ratio of two forms of amyloid protein in the spinal fluid. This ratio achieves 93% sensitivity and 100% specificity for Alzheimer’s pathology, making it one of the most accurate diagnostic tools available. The updated 2024 diagnostic criteria from the National Institute on Aging recognize CSF biomarkers, including the amyloid ratio and certain tau measurements, as sufficient on their own to biologically diagnose Alzheimer’s disease.
A lumbar puncture sounds intimidating, but the procedure itself takes about 20 to 30 minutes. The main downside is that it’s more invasive than a blood draw, which is why blood-based tests are gradually becoming the preferred first-line screening tool.
Amyloid PET Brain Scans
An amyloid PET scan uses a radioactive tracer to directly visualize amyloid plaque buildup in the brain. Results are measured on a standardized scale called Centiloids, where scores roughly between 10 and 30 represent a transitional zone from sparse to moderate plaque levels, and higher scores indicate significant amyloid burden. This scan provides both a yes-or-no answer about amyloid presence and spatial detail about where in the brain plaques have accumulated.
Medicare recently removed restrictions that had limited coverage of amyloid PET scans to one per lifetime and only within approved research studies. Coverage decisions are now made by regional Medicare contractors, which may allow for broader access. That said, these scans remain expensive, and coverage through private insurance varies. If your neurologist recommends one, it’s worth checking with your insurer beforehand.
A second type of PET scan, tau PET, detects the other hallmark protein of Alzheimer’s and is used primarily for staging how far the disease has progressed rather than for initial diagnosis.
Genetic Testing for Familial Alzheimer’s
Early-onset Alzheimer’s is more likely than the late-onset form to have a direct genetic cause. Three genes, known as APP, PSEN1, and PSEN2, cause autosomal dominant Alzheimer’s disease when mutated. If you carry one of these mutations, you will almost certainly develop Alzheimer’s, typically at an age similar to when your affected parent developed it. PSEN1 mutations are the most common and can cause symptoms as early as the late 30s or 40s. In families with these mutations, affected members often develop the disease at remarkably consistent ages across generations.
Genetic testing is most relevant if you have a strong family history of early-onset Alzheimer’s, meaning a parent, sibling, or multiple relatives who developed dementia before 65. A screening study published in PLOS Medicine identified APP, PSEN1, or PSEN2 mutations in 53 families with early-onset Alzheimer’s. The most frequently found APP mutation appeared in 11 unrelated families, illustrating that certain mutations recur across different populations.
If you’re considering genetic testing, formal genetic counseling is strongly recommended both before and after the test. For people without symptoms who want to know their risk, guidelines recommend a two-session pre-test counseling protocol modeled on protocols originally developed for Huntington’s disease testing. This gives you time to fully consider the implications before receiving results. After results are disclosed, counseling addresses how you might share the information with family members and sets up a follow-up plan.
What a Diagnosis Looks Like Now
The framework for diagnosing Alzheimer’s shifted fundamentally in 2024. Updated criteria from the National Institute on Aging now define Alzheimer’s by its biology rather than its symptoms. A single positive result on any “Core-1” biomarker, including an amyloid PET scan, the CSF amyloid ratio, or a validated blood test like p-tau217, is sufficient for a biological diagnosis. This means Alzheimer’s can be diagnosed even before symptoms appear, which is a major change from the historical approach of diagnosing only after significant cognitive decline.
The new framework also separates biological staging (how much amyloid and tau pathology is present) from clinical staging (how much the disease is affecting daily life). Your doctor can now tell you not just whether you have Alzheimer’s biology, but how advanced the underlying brain changes are, even if your symptoms are mild. This is especially relevant for early-onset cases, where catching the disease at an earlier biological stage may open the door to treatments designed to slow progression.
For someone concerned about early-onset Alzheimer’s, the practical path forward starts with your primary care doctor. Describe your specific symptoms, mention any family history of dementia (especially before age 65), and ask about cognitive screening and biomarker testing. The combination of tools now available means that an accurate diagnosis no longer has to wait until the disease is advanced.